Brooklyn ImmunoTherapeutics, Inc. (NYSEAMERICAN:BTX) traded up 5.2% during mid-day trading on Wednesday . The stock traded as high as $17.85 and last traded at $17.26. 25,519 shares were traded during trading, a decline of 100% from the average session volume of 8,357,578 shares. The stock had previously closed at $16.40.
In other Brooklyn ImmunoTherapeutics news, Director Charles Cherington sold 200,000 shares of the company’s stock in a transaction dated Wednesday, June 16th. The shares were sold at an average price of $15.73, for a total transaction of $3,146,000.00. Following the transaction, the director now directly owns 6,094,101 shares in the company, valued at approximately $95,860,208.73. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Several large investors have recently made changes to their positions in the stock. Geode Capital Management LLC acquired a new stake in shares of Brooklyn ImmunoTherapeutics in the 1st quarter valued at approximately $39,000. Virtu Financial LLC bought a new stake in Brooklyn ImmunoTherapeutics during the 1st quarter worth approximately $68,000. Renaissance Technologies LLC bought a new stake in Brooklyn ImmunoTherapeutics during the 1st quarter worth approximately $74,000. Finally, Citadel Advisors LLC bought a new stake in Brooklyn ImmunoTherapeutics during the 1st quarter worth approximately $85,000.
Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
Read More: Tariff
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.